IBM Q3 Earnings: $2.65 EPS Tops Estimates; Revenue up 9.1%
In Q3, IBM delivered $2.65 EPS, beating estimates by $0.20 on $16.33B revenue, up 9.1% year-over-year. Cullen Frost Bankers grew its IBM stake by 3.8% (3,227 shares) and Global Assets Advisory upped holdings 33.5% (3,024 shares), as RBC and BMO raised price targets to $350 and $305.
1. Institutional Investors Ramp Up Holdings
In the third quarter, several institutional investors increased their stakes in International Business Machines Corporation. Cullen Frost Bankers Inc. lifted its share count by 3.8%, adding 3,227 shares to reach a total of 88,856 shares valued at $25.07 million. Global Assets Advisory LLC boosted its position by 33.5%, purchasing 3,024 additional shares to hold 12,044 shares worth $3.40 million. Overall, institutional ownership stands at 58.96% of IBM’s outstanding stock, underscoring continued confidence from large asset managers in the company’s strategic direction.
2. Q3 Earnings Exceed Street Estimates
In its latest quarterly report, IBM delivered earnings per share of $2.65, surpassing the consensus estimate by $0.20. Revenue for the period reached $16.33 billion, up 9.1% year-over-year and ahead of analyst projections of $16.10 billion. The company reported a net margin of 12.09% and a return on equity of 37.76%, reflecting ongoing improvements in profitability. Management highlighted that operating margin has been expanding steadily, driven by growth in cloud and cognitive software segments.
3. Analyst Ratings and Price Targets Point Higher
Following the earnings release, Wall Street analysts have revised their outlook on IBM. Royal Bank of Canada raised its price target to $350 and maintained an "Outperform" rating, while Jefferies Financial Group upgraded the stock to "Buy" with a target of $360. BMO Capital Markets reiterated a "Market Perform" rating and lifted its target to $305. Of the 19 analysts covering IBM, one rates it a Strong Buy, 12 give Buy ratings, five maintain Holds and one issues a Sell, resulting in a consensus target price of $306.86.